CORRESP Filing
ANAVEX LIFE SCIENCES CORP.
Date: July 21, 2025 · CIK: 0001314052 · Accession: 0001731122-25-001001
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-288661
Letter
ANAVEX LIFE SCIENCES CORP. 630 5th Avenue, 20th Floor
New York, NY USA 10111
July 21, 2025
VIA EDGAR
United States Securities and Exchange Commission
100 F Street N.E.
Washington, D.C. 20549
Attn: Jessica Dickerson
Re: Anavex Life Sciences Corp.
Request for Acceleration of Registration Statement on Form S-3
File No. 333-288661
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended, Anavex Life Sciences Corp., a Nevada corporation (the " Company "), hereby requests acceleration of the effectiveness of its Registration Statement on Form S-3 (File No. 333-288661), filed with the U.S. Securities and Exchange Commission on July 14, 2025, to 4:00 P.M. ET on July 23, 2025 or as soon thereafter as practicable.
Please direct any questions or comments regarding this filing to Clayton Parker, Esq. at (305) 794-6293 or Clayton.Parker@klgates.com of K&L Gates LLP, legal counsel to the Company.
Sincerely,
/s/ Christopher Missling, PhD
Show Raw Text
CORRESP 1 filename1.htm ANAVEX LIFE SCIENCES CORP. 630 5th Avenue, 20th Floor New York, NY USA 10111 July 21, 2025 VIA EDGAR United States Securities and Exchange Commission 100 F Street N.E. Washington, D.C. 20549 Attn: Jessica Dickerson Re: Anavex Life Sciences Corp. Request for Acceleration of Registration Statement on Form S-3 File No. 333-288661 Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended, Anavex Life Sciences Corp., a Nevada corporation (the " Company "), hereby requests acceleration of the effectiveness of its Registration Statement on Form S-3 (File No. 333-288661), filed with the U.S. Securities and Exchange Commission on July 14, 2025, to 4:00 P.M. ET on July 23, 2025 or as soon thereafter as practicable. Please direct any questions or comments regarding this filing to Clayton Parker, Esq. at (305) 794-6293 or Clayton.Parker@klgates.com of K&L Gates LLP, legal counsel to the Company. Sincerely, /s/ Christopher Missling, PhD Christopher Missling, PhD Chief Executive Officer